HRP20110432T1 - Antitumorske kombinacije koje sadrže sredstvo za inhibiranje vegf i irinotekan - Google Patents
Antitumorske kombinacije koje sadrže sredstvo za inhibiranje vegf i irinotekan Download PDFInfo
- Publication number
- HRP20110432T1 HRP20110432T1 HR20110432T HRP20110432T HRP20110432T1 HR P20110432 T1 HRP20110432 T1 HR P20110432T1 HR 20110432 T HR20110432 T HR 20110432T HR P20110432 T HRP20110432 T HR P20110432T HR P20110432 T1 HRP20110432 T1 HR P20110432T1
- Authority
- HR
- Croatia
- Prior art keywords
- irinotecan
- combinations containing
- inhibiting agent
- vegf trap
- treatment
- Prior art date
Links
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title claims abstract 5
- 229960004768 irinotecan Drugs 0.000 title claims abstract 5
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 5
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 230000001613 neoplastic effect Effects 0.000 claims abstract 4
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 231100000196 chemotoxic Toxicity 0.000 claims 1
- 230000002604 chemotoxic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0704868A FR2918279B1 (fr) | 2007-07-05 | 2007-07-05 | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| PCT/FR2008/000943 WO2009024667A2 (fr) | 2007-07-05 | 2008-07-02 | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110432T1 true HRP20110432T1 (hr) | 2011-07-31 |
Family
ID=38961256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110432T HRP20110432T1 (hr) | 2007-07-05 | 2011-06-09 | Antitumorske kombinacije koje sadrže sredstvo za inhibiranje vegf i irinotekan |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20100160233A1 (ko) |
| EP (1) | EP2173349B1 (ko) |
| JP (4) | JP2010532335A (ko) |
| KR (4) | KR20150048910A (ko) |
| CN (3) | CN103623392A (ko) |
| AR (1) | AR067420A1 (ko) |
| AT (1) | ATE500829T1 (ko) |
| AU (1) | AU2008290442B2 (ko) |
| BR (1) | BRPI0812835B8 (ko) |
| CA (1) | CA2693152C (ko) |
| CY (1) | CY1111675T1 (ko) |
| DE (1) | DE602008005457D1 (ko) |
| DK (1) | DK2173349T3 (ko) |
| ES (1) | ES2362637T3 (ko) |
| FR (1) | FR2918279B1 (ko) |
| HR (1) | HRP20110432T1 (ko) |
| IL (2) | IL203132A (ko) |
| MX (1) | MX2009013950A (ko) |
| PL (1) | PL2173349T3 (ko) |
| PT (1) | PT2173349E (ko) |
| RS (1) | RS51777B (ko) |
| RU (1) | RU2471483C2 (ko) |
| SI (1) | SI2173349T1 (ko) |
| WO (1) | WO2009024667A2 (ko) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277551B1 (en) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
| JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス， インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
| EP2344161B1 (en) * | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| ES2354922B1 (es) | 2009-09-02 | 2012-02-07 | Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron | Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer. |
| US20130029909A1 (en) * | 2009-09-15 | 2013-01-31 | John Ryan | Treatment of cancer |
| EP4360709A3 (en) | 2011-01-13 | 2024-07-03 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| MA40354A (fr) | 2014-07-18 | 2017-05-24 | Sanofi Sa | Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE293164T1 (de) * | 1999-06-08 | 2005-04-15 | Regeneron Pharma | Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften |
| BR0308133A (pt) * | 2002-03-01 | 2005-01-04 | Pharmacia Italia Spa | Forma polimórfica cristalina de cloridrato de irinotecan |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| WO2005016369A1 (en) * | 2003-08-06 | 2005-02-24 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
| AU2005265071A1 (en) * | 2004-06-18 | 2006-01-26 | Memorial Sloan-Kettering Cancer Center | VEGF inhibitors for the treatment of malignant pleural effusion |
| FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
-
2007
- 2007-07-05 FR FR0704868A patent/FR2918279B1/fr active Active
-
2008
- 2008-07-02 KR KR1020157010064A patent/KR20150048910A/ko not_active Application Discontinuation
- 2008-07-02 EP EP08827826A patent/EP2173349B1/fr active Active
- 2008-07-02 KR KR1020107000011A patent/KR20100031123A/ko not_active Application Discontinuation
- 2008-07-02 KR KR1020167017056A patent/KR20160079918A/ko not_active Application Discontinuation
- 2008-07-02 CN CN201310556556.4A patent/CN103623392A/zh active Pending
- 2008-07-02 CN CN201610141168.3A patent/CN105833244A/zh active Pending
- 2008-07-02 MX MX2009013950A patent/MX2009013950A/es active IP Right Grant
- 2008-07-02 AT AT08827826T patent/ATE500829T1/de active
- 2008-07-02 WO PCT/FR2008/000943 patent/WO2009024667A2/fr active Application Filing
- 2008-07-02 DK DK08827826.2T patent/DK2173349T3/da active
- 2008-07-02 ES ES08827826T patent/ES2362637T3/es active Active
- 2008-07-02 DE DE602008005457T patent/DE602008005457D1/de active Active
- 2008-07-02 AU AU2008290442A patent/AU2008290442B2/en active Active
- 2008-07-02 RU RU2010103781/15A patent/RU2471483C2/ru active Protection Beyond IP Right Term
- 2008-07-02 CN CN200880023537A patent/CN101686975A/zh active Pending
- 2008-07-02 RS RS20110215A patent/RS51777B/en unknown
- 2008-07-02 CA CA2693152A patent/CA2693152C/fr not_active Expired - Fee Related
- 2008-07-02 BR BRPI0812835A patent/BRPI0812835B8/pt active IP Right Grant
- 2008-07-02 SI SI200830256T patent/SI2173349T1/sl unknown
- 2008-07-02 JP JP2010514042A patent/JP2010532335A/ja active Pending
- 2008-07-02 PT PT08827826T patent/PT2173349E/pt unknown
- 2008-07-02 KR KR1020187026491A patent/KR20180105261A/ko not_active Application Discontinuation
- 2008-07-02 PL PL08827826T patent/PL2173349T3/pl unknown
- 2008-07-04 AR ARP080102894A patent/AR067420A1/es not_active Application Discontinuation
-
2010
- 2010-01-04 IL IL203132A patent/IL203132A/en active IP Right Grant
- 2010-01-04 US US12/651,767 patent/US20100160233A1/en not_active Abandoned
-
2011
- 2011-06-08 CY CY20111100551T patent/CY1111675T1/el unknown
- 2011-06-09 HR HR20110432T patent/HRP20110432T1/hr unknown
-
2014
- 2014-01-13 US US14/153,795 patent/US20140127202A1/en not_active Abandoned
- 2014-08-29 JP JP2014174963A patent/JP2014240422A/ja active Pending
-
2015
- 2015-08-31 IL IL240965A patent/IL240965A0/en unknown
-
2016
- 2016-11-16 JP JP2016222826A patent/JP2017052789A/ja active Pending
-
2018
- 2018-08-15 JP JP2018152805A patent/JP2019006785A/ja active Pending
-
2019
- 2019-02-11 US US16/272,315 patent/US20190275147A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110432T1 (hr) | Antitumorske kombinacije koje sadrže sredstvo za inhibiranje vegf i irinotekan | |
| MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
| ATE510538T1 (de) | Zusammensetzungen und verfahren für nervenschutz | |
| MX345535B (es) | Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso. | |
| MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
| MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
| IN2014DN06501A (ko) | ||
| WO2015095227A3 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
| EA201491819A1 (ru) | Фармацевтические композиции для комбинированного лечения | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| SG148169A1 (en) | Combination drug therapy to treat obesity | |
| CL2007002513A1 (es) | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. | |
| MX2021000715A (es) | Composiciones y metodos para tratar trastornos metabolicos. | |
| MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| JO2721B1 (en) | Derivatives of artemisia plant and its preparations and therapeutic applications | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
| EP3818991A3 (en) | Compositions and methods for treating diseases |